EDIT Stock Analysis: Buy, Sell, or Hold?
EDIT - Editas Medicine, Inc. Common Stock
$2.80
0.11 (4.09%)
▲
5d:
+12.0%
30d:
+7.69%
90d:
+19.66%
HOLD
MODERATE Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When EDIT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: EDIT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: EDIT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: EDIT is currently trading at $2.80, which is considered fair relative to its 30-day fair value range of $2.45 to $3.11.
Technical Outlook: Technically, EDIT is in a strong uptrend. The price is approaching resistance at $2.88. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.1% recently.
Market Sentiment: EDIT has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $5.78 (+106.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, EDIT is in a strong uptrend. The price is approaching resistance at $2.88. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.1% recently.
Market Sentiment: EDIT has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $5.78 (+106.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.45 -
$3.11
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
55.3%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.1%)
- BULLISH: Trading 106.4% below Wall St target ($5.78)
Trading Range Analysis
30-Day Trading Range
$2.45 -
$3.11
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$2.35
Resistance Level
$2.88
Current Trend
Strong Uptrend
Technical data as of
Jun 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.99
Wall Street Target
$5.78
(+106.4%)
Revenue Growth (YoY)
-39.2%
Profit Margin
-281.6%
Share & Embed Analysis
Last updated: June 23, 2026 8:22 AM ET
Data refreshes hourly during market hours. Next update: 9:22 AM
Data refreshes hourly during market hours. Next update: 9:22 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EDIT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Amy Parison
SELL
474 shares
2026-03-03
Gilmore Neil O'neill
SELL
5394 shares
2026-03-03
Linda Burkly
SELL
749 shares
2026-03-03
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 56 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 64 BUY |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 53 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 56 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
